Founded in 2021 by Michael Mager, Benjamin Rapoport and Mark Hettick, the company is well-positioned in the growing neurotech market. In December 2024, Precision Neuroscience raised $102M in Series C funding, bringing total capitalization to $183M across six rounds, with ~117 employees as of January 2026.
Cyborg Score Rationale
Precision Neuroscience demonstrates strong technical execution with proprietary minimally-invasive BCI architecture, substantial capital backing ($183M raised), and emerging clinical partnerships. The BCI market growth trajectory (projected to expand from $2.3B in 2024 to $4.5B by 2029) provides favorable tailwinds, though the company remains pre-commercial and competitive intensity is rising.
Top Insights
Series C funding of $102M in December 2024 positions company for scaled clinical trials and commercialization pathway